Zymeworks Inc.
ZYMEHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeZymeworks Inc., a biotechnology company, develops biotherapeutics for the treatment of cancer, inflammation, and autoimmune diseases. Valued at $2.01B, ZYME is a mid-cap name in its sector. The company's platforms include Azymetric multispecific antibody platform; Drug Conjugate platform that includes a suite of proprietary cytotoxins comprising topoisomerase and microtubulin inhibiting toxins, stable linkers, and conjugation technologies; EFECT platform, which consists of a set of modifications to the Fc region of antibodies; and ProTECT, a tumor-specific immune co-stimulation platform.
Market Cap
$2.01B
Beta
1.19
P/E (TTM)
—
P/E (Fwd)
24.10
EPS (TTM)
$-2.02
EPS (Fwd)
$1.17
ROE
-72.3%
ROA
-24.1%
Cash
$270.7M
Total Debt
$16.0M
Free CF
-$65.1M
52W Change
92.2%
Annual Financials
Cash vs Debt
Where ZYME stands vs its 150-day and 200-day moving averages
As of the September 3, 2026 close, ZYME finished 24.85% above its 150-day moving average ($24.87) and 24.70% above its 200-day moving average ($24.90). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is ZYME overbought or oversold?
At the September 3, 2026 close, ZYME's RSI(14) was 71.1, in overbought territory (above 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
Zymeworks Inc. holds $270.7M in cash against $16.0M in total debt, giving it a net cash position. This means the company could theoretically pay off all its debt and still have cash remaining. Free cash flow is running at -$65.1M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. Return on equity stands at -72.3%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Revenue has been uneven over recent years, ranging from $412.5M to $106.0M.
The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. No single metric tells the full story. Reviewing ZYME's risk profile alongside its fundamentals and technical indicators provides a more complete picture.